June 5, 2017 / 11:11 AM / 2 months ago

BRIEF-Incyte Corp updates on Echo-202 trial of Incyte’s Epacadostat in combination with Merck’s Keytruda

1 Min Read

June 5 (Reuters) - Incyte Corp:

* Updated data from Echo-202 trial of Incyte’s Epacadostat in combination with Merck’s Keytruda® (Pembrolizumab) demonstrate clinical activity across multiple tumor types

* ‍responses observed with combination of Ido1 enzyme inhibition and Anti-Pd-1 therapy support advancing into Broad Phase 3 program​

* ‍safety data for this novel investigational immunotherapy combination are generally similar to Keytruda monotherapy​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below